AMSTERDAM, Netherlands, July 7 (UPI) -- Dutch firm Agendia said Friday it has licensed a genetic profile that can predict resistance to breast-cancer drug Tamoxifen.
Agendia said it has signed an exclusive license agreement with Erasmus MC University Medical Center in Rotterdam, Netherlands, for the genetic test that helps identify which breast-cancer patients are likely to fail Tamoxifen therapy.
The company said it would validate the test in collaboration with the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI/AVL) in Amsterdam.
After validation is complete, Agendia said it would market the genetic profile with the firm's branded product MammaPrint to expand its breast cancer-related product line.
"For Agendia, the tamoxifen-resistance profile is a valuable addition to its MammaPrint genetic profiling service that is used to assess the risk of metastasis in breast cancer patients," says Laura van't Veer, Agendia's chief operating officer. "Combining the tamoxifen-resistance profile with MammaPrint is a big step towards offering a more complete package to breast cancer patients that allows for reliable prognosis as well as specific advice on the most suitable adjuvant therapy."
Agendia added it would also collaborate with Erasmus MC and NKI/AVL on next-generation hormonal therapies for breast cancer.
